STUDIES OF CONCANAVALIN-A IN NONOBESE DIABETIC MICE .2. LYMPHOCYTE TRACKING AND PHENOTYPE RESPONSES

被引:0
|
作者
MUKHERJEE, B [1 ]
PEARCE, RB [1 ]
FORMBY, B [1 ]
PETERSON, CM [1 ]
机构
[1] SANSUM MED RES FDN,2219 BATH ST,SANTA BARBARA,CA 93105
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We studied the tracking of chromium-51-labeled (resting) and Con A-induced (activated) tritiated thymidine-labeled syngeneic lymphocytes to adrenal, blood, brain, heart, liver, lymph nodes, pancreas, spleen, testis/ovary, thymus and thyroid in prediabetic, nonobese diabetic (NOD) mice and in age- and sex-matched C57BL/6 mice. Chromium-51-labeled cells showed no significant difference between strains in tracking to any tissue except lymph nodes (decreased in NOD vs. C57, P < .05). Con A incubation resulted in no difference between strains in lymphocyte tracking to lymph nodes, but NOD mice had increased pancreatic tracking with Con A-incubated cells compared to C57 mice (P < .05). Female NOD mice had reduced thymic tracking (P = .001) compared to C57 controls. Positive selection experiments showed the Con A-responsive cell to be a T cell. Both Lyt2+ (CD8+) and L3T4+ (CD4+) enriched T cell populations showed a labeling response to Con A. After 48 h of Con A incubation, the L3T4+/Lyt2+ ratio increased in splenocytes from NOD mice (P < .05), whereas it decreased in C57 controls (P < .01). Over the course of 6 days in culture, NOD splenocytes exposed to Con A characteristically exhibited a delayed expansion of the Lyt2+ population. We conclude that Con A incubation of NOD splenocytes results in T cells that, when reinfused, avoid the thymus and track preferentially to the pancreas. Con A immunomodulation as potential treatment for autoimmune disease warrants further study in this murine model.
引用
收藏
页码:716 / 721
页数:6
相关论文
共 50 条
  • [1] STUDIES OF CONCANAVALIN-A IN NONOBESE DIABETIC MICE .1. PREVENTION OF INSULIN-DEPENDENT DIABETES
    PEARCE, RB
    PETERSON, CM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1991, 258 (02): : 710 - 715
  • [2] BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice
    Truong, Wayne
    Hancock, Wayne W.
    Plester, Jennifer C.
    Merani, Shaheed
    Rayner, David C.
    Thangavelu, Govindarajan
    Murphy, Kenneth M.
    Anderson, Colin C.
    Shapiro, A. M. James
    JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 86 (01) : 41 - 51
  • [3] LYMPHOCYTE-T VACCINATION IN NONOBESE DIABETIC MICE
    SMERDON, RA
    PEAKMAN, M
    VERGANI, D
    DIABETOLOGIA, 1992, 35 : A216 - A216
  • [4] MODULATING RENAL ALLOANTIGENS WITH CONCANAVALIN-A - MIXED LYMPHOCYTE CULTURE STUDIES
    NOWYGROD, R
    DOMBROVSKIS, S
    OLSON, LC
    TOLEDOPEREYRA, LH
    SIMMONS, RL
    SURGICAL FORUM, 1975, 26 : 325 - 328
  • [5] STUDIES ON THE ACCESSORY REQUIREMENT FOR LYMPHOCYTE-T ACTIVATION BY CONCANAVALIN-A
    GALLAGHER, RB
    WHELAN, A
    FEIGHERY, C
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1986, 66 (01): : 118 - 125
  • [6] MODULATION BY MACROPHAGES OF LYMPHOCYTE-RESPONSES TO PHYTOHEMAGGLUTININ, CONCANAVALIN-A AND SEMIALLOGENEIC CELLS
    HEM, E
    ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA SECTION C-IMMUNOLOGY, 1979, 87 (01): : 17 - 21
  • [7] STUDIES ON CHLOROPHYLLASE .2. INTERACTION OF THE ENZYME WITH CONCANAVALIN-A AND WITH N,N'-DICYCLOHEXYLCARBODIIMIDE
    TERPSTRA, W
    LAMBERS, JWJ
    LEVINE, YK
    PHOTOBIOCHEMISTRY AND PHOTOBIOPHYSICS, 1986, 11 (04): : 249 - 255
  • [8] STUDIES ON MECHANISM OF ACTIVATION OF LYMPHOCYTE MEMBRANE ATP-ASES BY CONCANAVALIN-A
    AVERDUNK, R
    MULLER, J
    WENZEL, B
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1976, 14 (07): : 339 - 344
  • [9] REGULATION OF LYMPHOCYTE-TRANSFORMATION RESPONSES TO PHYTOHEMAGGLUTININ, CONCANAVALIN-A OR LIPOPOLYSACCHARIDE BY NORMAL SERUM
    NEVEU, PJ
    PERDOUX, D
    REISS, D
    ANNALES D IMMUNOLOGIE, 1982, C133 (01): : 69 - 82
  • [10] AMPHOTERICIN-B MODIFICATIONS OF PERIPHERAL-BLOOD LYMPHOCYTE AND TONSIL LYMPHOCYTE-RESPONSES TO CONCANAVALIN-A
    SEAY, TE
    INMAN, FP
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1982, 4 (06): : 549 - 556